Back to today’s briefing

Story perspectives

Study Shows DMT Outperforms Placebo in Depression Treatment

2/25/2026

50 10 Full Breakdown

Summary

Story summary

A phase II trial sponsored by Small Pharma indicates dimethyltryptamine (DMT) may treat depression.
The 34-participant study shows DMT reduced symptoms more than placebo, according to researchers.
Researchers emphasize therapeutic support during the DMT experience, while psilocybin and MDMA trials continue.
The FDA previously approved Spravato, a ketamine nasal spray, for treatment-resistant depression.

1 of 1

Story summary

A phase II trial sponsored by Small Pharma indicates dimethyltryptamine (DMT) may treat depression.
The 34-participant study shows DMT reduced symptoms more than placebo, according to researchers.
Researchers emphasize therapeutic support during the DMT experience, while psilocybin and MDMA trials continue.
The FDA previously approved Spravato, a ketamine nasal spray, for treatment-resistant depression.